ARA-290 (16mg) Research Peptide | Elite Peptides

ARA-290 (16mg) Research Peptide – Elite Peptides

ARA-290 peptide, also known in scientific literature as cibinetide or helix B surface peptide (HBSP), is an 11-amino-acid chain derived from the beta domain of erythropoietin (EPO). Unlike the full EPO protein, which stimulates red blood cell production, ARA-290 focuses on tissue-regeneration pathways while avoiding erythropoiesis. Researchers value this peptide because it may support studies involving cellular repair, inflammation control, and pain management.

The peptide’s origin in the beta domain of EPO is significant. While EPO’s primary role is red blood cell stimulation, this domain appears to carry regenerative and protective signals without altering blood cell levels. ARA-290 may therefore offer scientists a way to study specific pathways related to healing and protection while excluding hematopoietic effects.

Laboratory studies have suggested that ARA-290 could potentially demonstrate:

• Regenerative properties that promote tissue healing.

• Anti-inflammatory activity by reducing inflammatory pathways.

• Anti-nociceptive effects that may impact pain signaling in experimental models.

• Cell-protective roles supporting homeostasis under stress conditions.

Researchers continue to explore whether ARA-290 may influence the immune system, promote recovery after injury, or protect against chronic conditions by reducing oxidative and inflammatory stress. Its design as a short peptide sequence provides stability and precise action, making it valuable for experimental modeling.

Important Notice:
Elite Peptides provides ARA-290 (16mg) strictly for research and laboratory purposes only. This product is not intended for human consumption, medical, or veterinary use.